Rocket Pharma names Aaron Ondrey CFO; expands leadership team for commercial transition

ROCKET PHARMACEUTICALS, INC.

Aaron Ondrey appointed CFO, effective March 25, 2024; previously CFO of Mirati Therapeutics.
Compensation: base salary $485k, target bonus 45%, equity grant ~$2.5M (half options, half RSUs) with 3-year vesting.
Other appointments: Kinnari Patel as President/Head of R&D/COO; Jonathan Schwartz as Chief Medical & Gene Therapy Officer; Mark White as GM Commercial; Martin Wilson as GC/Chief Corporate Officer.
Leadership changes position Rocket for planned commercial stage transition for gene therapies.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Aaron Ondrey

Chief Financial Officer

RCKT · ROCKET PHARMACEUTICALS, INC.

Effective: 2024-03-25
Filed: March 29, 2024, 7:59 PM ET

On March 25, 2024, Aaron Ondrey was appointed by Rocket Pharmaceuticals, Inc. (the “Company”) as the Company’s Chief Financial Officer and Principal Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Aaron Ondrey was appointed as Chief Financial Officer at ROCKET PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On March 25, 2024, Aaron Ondrey was appointed by Rocket Pharmaceuticals, Inc. (the “Company”) as the Company’s Chief Financial Officer and Principal Financial Officer.

View on SEC.gov

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-016666

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.